Age and baseline values predict 12 and 24-month functional changes in type 2 SMA-Reference-Cited by-同舟云学术

Age and baseline values predict 12 and 24-month functional changes in type 2 SMA

Published:2020-09 Issue:9 Volume:30 Page:756-764
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Coratti Giorgia,Pera Maria C,Lucibello Simona,Montes Jacqueline,Pasternak Amy,Mayhew Anna,Glanzman Allan M,Young Sally Dunaway,Pane Marika,Scoto Mariacristina,Messina Sonia,Goemans Nathalie,Osorio Andres Nascimiento,Pedemonte Marina,Sansone Valeria,Bertini Enrico,De Vivo Darryl C.,Finkel Richard,Muntoni Francesco,Mercuri Eugenio

Publisher

Elsevier BV

Subject

Genetics(clinical),Clinical Neurology,Neurology,Pediatrics, Perinatology, and Child Health

Reference18 articles.

1. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year;Kaufmann;Arch Neurol,2011

2. Prospective cohort study of spinal muscular atrophy types 2 and 3;Kaufmann;Neurology,2012

3. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study;Finkel;Lancet,2016

4. Nusinersen versus sham control in later-onset spinal muscular atrophy;Mercuri;N Engl J Med,2018

5. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1;Pechmann;Eur J Paediatr Neurol,2018

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis;Neurology and Therapy;2024-09-02

2. Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA;Neuromuscular Disorders;2024-08

3. Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study;Journal of Neurology;2024-07-19

4. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam;Journal of Neurology;2024-05-11

5. Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study;European Journal of Neurology;2024-04-24